Compare CARE & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CARE | IMMX |
|---|---|---|
| Founded | 1974 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.5M | 736.1M |
| IPO Year | 2020 | 2021 |
| Metric | CARE | IMMX |
|---|---|---|
| Price | $32.26 | $10.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $25.00 | $19.20 |
| AVG Volume (30 Days) | 440.6K | ★ 2.3M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.40% | N/A |
| EPS Growth | ★ 30.19 | N/A |
| EPS | ★ 3.88 | N/A |
| Revenue | ★ $20,315,000.00 | N/A |
| Revenue This Year | $12.50 | N/A |
| Revenue Next Year | $11.82 | N/A |
| P/E Ratio | $8.20 | ★ N/A |
| Revenue Growth | ★ 4.65 | N/A |
| 52 Week Low | $16.78 | $1.94 |
| 52 Week High | $35.03 | $12.14 |
| Indicator | CARE | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 56.76 | 54.73 |
| Support Level | $31.29 | $7.99 |
| Resistance Level | $35.03 | $10.61 |
| Average True Range (ATR) | 0.99 | 0.86 |
| MACD | -0.33 | 0.01 |
| Stochastic Oscillator | 25.53 | 35.83 |
Carter Bankshares Inc is a bank holding company that conducts its business solely through the bank. The Bank earns revenue from interest on loans and securities and fees charged for financial services provided to customers. It offers a full range of deposit services including Lifetime Free Checking, interest checking accounts, savings accounts, retirement accounts and other deposit accounts of various types, ranging from money market accounts to longer-term CDs. The Bank offers a full range of commercial and consumer loans. The Bank also originates and holds fixed and variable-rate mortgage loans and offers home equity lines of credit to its customers.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.